Introduction {#acn3452-sec-0001}
============

Members of the large kinesin protein superfamily (KIFs) are microtubule‐based mechanoenzymes that use ATP hydrolysis to power the transport of cargoes such as organelles, protein complexes, and mRNAs within cells. They are distinguished by a motor domain, which may be localized throughout the protein, as well as other domains which allow for selectivity of the materials transported.[1](#acn3452-bib-0001){ref-type="ref"} Given this crucial role in cellular transport, it is not surprising that alterations in KIFs have been implicated in a variety of inherited disorders, particularly affecting the nervous system. For instance, mutations in the gene encoding the brain‐specific kinesin KIF1A -- involved in anterograde axonal transport and learning enhancement[2](#acn3452-bib-0002){ref-type="ref"} -- lead to a variety of neurological syndromes, including hereditary sensory neuropathy (HSN2C, OMIM 614213), intellectual disability (MRD9, OMIM 614255), and hereditary spastic paraplegia (HSP) (SPG30, OMIM 610357).[3](#acn3452-bib-0003){ref-type="ref"}

The KIF1A protein comprises a motor domain at the N‐terminus (residues 1‐361), a forkhead‐associated (FHA) domain (residues 516‐572), and a pleckstrin homology (PH) domain (residues 1676‐1774). Patients presenting with cognitive impairment often exhibit a relatively severe phenotype with a range of additional symptoms including optic atrophy, cerebellar ataxia, and neuropathy; they frequently carry heterozygous missense mutations in the motor domain, suggestive of a dominant‐negative pathogenic mode of action.[3](#acn3452-bib-0003){ref-type="ref"}, [4](#acn3452-bib-0004){ref-type="ref"}, [5](#acn3452-bib-0005){ref-type="ref"} Several different families presenting with neuropathy alone, characterized by common features of profound sensory loss and ulcero‐mutilation, have harbored recessive truncating mutations in the alternatively spliced exon 25b.[6](#acn3452-bib-0006){ref-type="ref"}

In the initial report of HSP caused by *KIF1A* mutations (SPG30), Klebe and colleagues described two consanguineous families with autosomal recessive HSP due to homozygous mutations in *KIF1A*.[7](#acn3452-bib-0007){ref-type="ref"} The HSPs are a group of progressive gait disorders characterized by lower extremity spasticity in their "pure" form, along with cognitive symptoms, optic atrophy, and other neurologic findings in their "complex" form. They are among the most genetically diverse neurologic disorders, with almost 90 distinct genetic loci (SPG1‐78, plus others).[8](#acn3452-bib-0008){ref-type="ref"} Although \>60 HSP genes within these loci have been identified, a relatively small number of common cellular pathogenic themes have emerged, among them is the disruption of the proper morphology and distribution of organelles within the long axons of corticospinal neurons.[9](#acn3452-bib-0009){ref-type="ref"} In addition to spasticity, some of the originally described patients and those identified subsequently also displayed cerebellar ataxia, axonal neuropathy, or both.[10](#acn3452-bib-0010){ref-type="ref"}

More recently, dominantly inherited *KIF1A* mutations resulting in a HSP phenotype have been reported. Ylikallio et al.[11](#acn3452-bib-0011){ref-type="ref"} uncovered a c.206C\>T, p.Ser69Leu variant in *KIF1A* in a Finnish father and son with early‐onset pure HSP. This same variant was also observed in a multigeneration Sicilian family with a more variable phenotype, complicated in some members by psychomotor delay, hand amyotrophy, and sensory abnormalities.[12](#acn3452-bib-0012){ref-type="ref"} Finally, Iqbal et al.[13](#acn3452-bib-0013){ref-type="ref"} found that both c.80T\>C, p.Ile27Thr and c.22G\>A, p.Val8Met were associated with pure HSP in multigeneration families.

Here, we present a three‐generation family whose afflicted members each carry the heterozygous c.206C\>T, p.Ser69Leu mutation in *KIF1A*. The phenotype is most reminiscent of early‐onset pure HSP, although one affected member had only mild symptoms in childhood before developing more prominent spasticity and gait abnormalities in adulthood. This firmly establishes p.Ser69Leu as a pathogenic KIF1A variant, with typically early‐onset symptoms.

Case Report {#acn3452-sec-0002}
===========

Subjects provided informed consent to participate in a clinical research protocol (00‐N‐0043), approved by the NIH Combined NeuroScience Institutional Review Board, and were evaluated at the NIH Clinical Research Center.

Patient II.5 is the index subject (Fig. [1](#acn3452-fig-0001){ref-type="fig"}A). He was the product of a normal pregnancy but developed abnormal gait and frequent falls at 3 years of age. His gait abnormalities gradually progressed. By the age of 40, he was using a cane to steady himself, and by his late 50s he required a wheel chair. By report, evaluation at age 52 revealed hyperreflexia, a pyramidal pattern of weakness, and spastic gait. Serum studies including vitamin B~12~, folate, ceruloplasmin, RPR, HTLV I/II serologies, and ANA titers were unrevealing. MRI of the brain was normal, while cervical spine MRI was notable for stenosis from C3 to C6, without spinal cord impingement. On examination in our clinic at age 61, he exhibited normal cognition and language. Motor examination revealed full power in the upper extremities. However, in the lower extremities, he was symmetrically weak on hip flexion (MRC grade 5‐/5), dorsiflexion (2/5), and plantar flexion (4‐/5); foot eversion and inversion were immobile (0/5). He had prominent scoliosis. Sensory examination was notable for decreased vibratory sensation at the great toes. There was diffuse hyperreflexia, with sustained clonus at the ankles and extensor plantar responses. There was no dysmetria. He was nonambulatory.

![A three‐generation family with pure HSP and pathogenic *KIF1A* missense mutation. (A) Affected subjects II.5, III.2, and IV.2 are heterozygous for the c.206 C\>T, p.Ser69Leu missense variant. (B) Head MRI of II.2, with representative sagittal T1 (left) and axial T2 FLAIR (right) images shown. (C) Amino acid residues (single letter code) of the motor domain around the p.Ser69Leu mutation in KIF1A are shown for the indicated species, with residue numbers at the left. Highly conserved residues are in green, with asterisks directly above. Residues at position 69 (human sequence numbering) are in red, with the pathogenic mutation indicated above.](ACN3-4-821-g001){#acn3452-fig-0001}

Patient III.2 is a daughter of II.5, and she was 35 years old at evaluation. She developed normally throughout childhood. However, in her teenage years, her running became strained. By her early 20s, she noted cramps in her legs and feet as well as trouble walking upstairs. On examination, she had normal cognition and exhibited full strength. Reflexes were increased only at the patella and ankles, but plantar responses were extensor bilaterally. There were no sensory abnormalities, and her coordination was normal. Her gait was mildly spastic, with toe walking. Head MRI was normal (Fig. [1](#acn3452-fig-0001){ref-type="fig"}B).

Patient IV.2 is a 6‐year‐old daughter of III.2 conceived via in vitro fertilization. During her mother\'s pregnancy, there was in utero demise of a twin. She walked at 13 months, but by 3 years of age, she preferred walking on her toes. She also complained of pain in the back of her legs, and has four developmentally absent spinous processes in her back. On examination, she had full muscle power but tone was increased in her lower extremities. Reflexes in the lower extremities were brisk, with cross adductors and extensor plantar responses. She walked on her toes with a mildly spastic gait. By report, head MRI was normal, with the exception of a possibly low‐lying cerebellum (without Chiari malformation).

Patient IV.2 underwent commercial genetic testing for common autosomal dominant HSPs including SPG3A, SPG4 (deletion/duplication and sequencing), SPG6, SPG8, SPG17, and SPG31, which was negative. Blood was drawn for DNA isolation and exome sequencing from the patient described above as well as II.5 and III.2. Two clearly unaffected, first‐degree relatives (II.6 and III.3, ages 56 and 33, respectively) of different generations were also selected for targeted testing to facilitate segregation analysis of possible pathogenic variants. Subject IV.1, who was 4 years old at evaluation and unaffected clinically, was not tested for the *KIF1A* variant.

Exome sequencing was performed after target capture using an Agilent SureSelect or Illumina TruSeq kit and run on an Illumina HiSeq2000 or HiSeq2500 per the manufacturer\'s instructions, employing 101‐bp paired‐end read sequencing. Reads were mapped to the reference genome using the Burrows‐Wheeler Aligner and processed using the Genome Analysis Toolkit. Missense variants were sought in public databases to determine minor allele frequencies (ExAC, EVS) and interrogated in silico to predict any damaging effects (SIFT, PolyPhen‐2, Mutation Taster, and CDPred) as described previously.[14](#acn3452-bib-0014){ref-type="ref"} Sanger sequencing was performed for confirmation of mutations (GeneDx, Gaithersburg, MD). Genes screened via exome sequencing included: *ABCD1, ACOX1, AP4B1, AP4E1, AP4M1, AP4S1, AP5Z1, ATL1, B4GALNT1, BSCL2, C12orf65, CCT5, CLPP, CYP2U1, CYP7B1, DDHD1, DDHD2, ERLIN2, FA2H, FBXO7, GAD1, GAN, GBA2, GJC2, HARS2, HSPD1, KDM5C, KIAA0196, KIF1A, KIF5A, LARS2, MARS2, NIPA1, OPA3, PLP1, PNPLA6, PSEN1, REEP1, RTN2, SLC16A2, SLC19A3, SLC2A1, SLC33A1, SPAST, SPG11, SPG20, SPG21, SPG7, STXBP1, TECPR2, TFG, TTR, VAMP1, VPS37A, ZFYVE26,* and *ZFYVE27*.

A *KIF1A* c.206C\>T, p.Ser69Leu heterozygous mutation was identified in all affected members but was absent from unaffected subjects II.6 and III.3. This variant is not found in the ExAC database, and it has a Combined Annotation‐Dependent Depletion (CADD)[15](#acn3452-bib-0015){ref-type="ref"} score of 16.32.

Discussion {#acn3452-sec-0003}
==========

We present a family with pure HSP and an autosomal dominant pattern of inheritance. Furthermore, we have demonstrated segregation of the c.206 C\>T, p.Ser69Leu mutation among affected family members spanning three generations, as well as its absence in two unaffected subjects. All other candidate genes examined either did not show pathogenic mutations or else the identified variants did not segregate among affected members. In silico analysis of this mutation in the N‐terminal motor domain of KIF1A suggests that it may affect the L2 loop which forms part of the ATP‐binding pocket, possibly by breaking the interaction between Tyr67 and ATP.[11](#acn3452-bib-0011){ref-type="ref"} Importantly, our identification of an additional family with this mutation is informative because unlike many residues mutated within the motor domain, Ser69 is not as highly conserved, with some variation across species at this position and at neighboring residues (Fig. [1](#acn3452-fig-0001){ref-type="fig"}C).

When taken together with the two previous reports of HSP patients with p.Ser69Leu mutation in KIF1A,[11](#acn3452-bib-0011){ref-type="ref"}, [12](#acn3452-bib-0012){ref-type="ref"} these additional cases strongly support pathogenicity of p.Ser69Leu autosomal dominant SPG30 and furthermore suggest that this may represent a mutation hot spot. Intriguingly, most of these cases differ substantially from typical presentations of patients with heterozygous missense mutations in the motor domain, as these patients typically have a far more severe phenotype with prominent cognitive impairment and other associated neurologic findings.[3](#acn3452-bib-0003){ref-type="ref"}, [4](#acn3452-bib-0004){ref-type="ref"}, [5](#acn3452-bib-0005){ref-type="ref"}, [16](#acn3452-bib-0016){ref-type="ref"} Perhaps, the fact that Ser69 is not invariant and occurs within a small segment of the motor domain that appears relatively divergent (Fig. [1](#acn3452-fig-0001){ref-type="fig"}C) mitigates the functional effects of this mutation. The identification of additional patients with missense mutations in this critical domain will likely facilitate more precise genotype--phenotype correlations.
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